Ramucirumab
Summary
Risk. The use of amino acids, proteins, and peptides is not considered to pose any environmental impact.
This summary information comes from fass.se.
Detailed information
Assessment report
Assessment report for Cyramza (ramucirumab), 17 December 2015, EMA/CHMP/69143/2016.
"No ERA was submitted."
Fass environmental information
Fass environmental information for Cyramza from Lilly (downloaded 2019-09-04).
Risk
The use of amino acids, proteins, and peptides is not considered to pose any environmental impact.
Detailed information
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
References
- European Medicines Agency. European public assessment reports (EPAR). Cyramza (ramucirumab), 17 December 2015, EMA/CHMP/69143/2016.
- Fass för vårdpersonal.
- European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.
Author: Health and Medical Care Administration, Region Stockholm